OBJECTIVE: Intraoperative imaging of intravascular thrombi is limited by the inability of visible light to penetrate thick-walled vessels. Near-infrared (NIR) light has relatively high tissue penetration and low autofluorescence and scatter, offering significant advantages. We hypothesized that the development of 700-nm NIR fluorophores for platelet labeling, in conjunction with existing 800-nm NIR fluorophores, would permit simultaneous and separable quantitation of intravascular thrombi and measurement of the antiplatelet effect of drugs. METHODS: We synthesized a series of lipophilic, cationic, polymethine indocyanine dyes (MHI-86, 94, 106, and 114) that emit at approximately 700 nm. Platelet uptake was optimized in vitro and the bioactivity and blood half-life of labeled platelets was characterized in vitro and in vivo. FeCl(3)-induced injury of the femoral arteries and intravascular thrombus formation was performed in 35-kg Yorkshire pigs. A combination of 700-nm and 800-nm NIR fluorophore-labeled platelets was used in conjunction with the fluorescence-assisted resection and exploration imaging system to image and quantify the antiplatelet effect of cilostazol and acetylsalicylic acid. RESULTS: MHI-114 was incorporated at nearly 4.1 × 10(6) molecules per platelet without affecting platelet function. When infused into pigs, the signal-to-background ratio of MHI-114-labeled platelets exhibited a blood half-life of 16.4 ± 2.2 (mean ± SEM; n = 3) minute and generated a signal-to-background ratio of 2.5 ± 0.5 (mean ± SEM; n = 3) at the site of thrombi. Using dual-NIR-labeled platelet populations, cilostazol and acetylsalicylic acid were found to cause a reduction in platelet incorporation into thrombi of 51 ± 2% and 10 ± 1% (mean ± SEM; n = 3), respectively, relative to vehicle-only treated control thrombi. CONCLUSIONS: New platelet-avid 700-nm NIR fluorophores permit simultaneous two-wavelength NIR fluorescence imaging and quantitation of intravascular thrombi in intact vessels approaching the size of humans and can be used to study the antiplatelet effect of drugs.
OBJECTIVE: Intraoperative imaging of intravascular thrombi is limited by the inability of visible light to penetrate thick-walled vessels. Near-infrared (NIR) light has relatively high tissue penetration and low autofluorescence and scatter, offering significant advantages. We hypothesized that the development of 700-nm NIR fluorophores for platelet labeling, in conjunction with existing 800-nm NIR fluorophores, would permit simultaneous and separable quantitation of intravascular thrombi and measurement of the antiplatelet effect of drugs. METHODS: We synthesized a series of lipophilic, cationic, polymethine indocyanine dyes (MHI-86, 94, 106, and 114) that emit at approximately 700 nm. Platelet uptake was optimized in vitro and the bioactivity and blood half-life of labeled platelets was characterized in vitro and in vivo. FeCl(3)-induced injury of the femoral arteries and intravascular thrombus formation was performed in 35-kg Yorkshire pigs. A combination of 700-nm and 800-nm NIR fluorophore-labeled platelets was used in conjunction with the fluorescence-assisted resection and exploration imaging system to image and quantify the antiplatelet effect of cilostazol and acetylsalicylic acid. RESULTS:MHI-114 was incorporated at nearly 4.1 × 10(6) molecules per platelet without affecting platelet function. When infused into pigs, the signal-to-background ratio of MHI-114-labeled platelets exhibited a blood half-life of 16.4 ± 2.2 (mean ± SEM; n = 3) minute and generated a signal-to-background ratio of 2.5 ± 0.5 (mean ± SEM; n = 3) at the site of thrombi. Using dual-NIR-labeled platelet populations, cilostazol and acetylsalicylic acid were found to cause a reduction in platelet incorporation into thrombi of 51 ± 2% and 10 ± 1% (mean ± SEM; n = 3), respectively, relative to vehicle-only treated control thrombi. CONCLUSIONS: New platelet-avid 700-nm NIR fluorophores permit simultaneous two-wavelength NIR fluorescence imaging and quantitation of intravascular thrombi in intact vessels approaching the size of humans and can be used to study the antiplatelet effect of drugs.
Authors: Per Kristian Hol; Per Snorre Lingaas; Runar Lundblad; Kjell Arne Rein; Karleif Vatne; Hans-Jørgen Smith; Sigurd Nitter-Hauge; Erik Fosse Journal: Ann Thorac Surg Date: 2004-08 Impact factor: 4.330
Authors: S Massberg; G Enders; F C Matos; L I Tomic; R Leiderer; S Eisenmenger; K Messmer; F Krombach Journal: Blood Date: 1999-12-01 Impact factor: 22.113
Authors: Eric A Owens; Hoon Hyun; Tyler L Dost; Jeong Heon Lee; GwangLi Park; Dang Huan Pham; Min Ho Park; Hak Soo Choi; Maged Henary Journal: J Med Chem Date: 2016-05-19 Impact factor: 7.446
Authors: Yoshitomo Ashitate; Andrew Levitz; Min Ho Park; Hoon Hyun; Vivek Venugopal; GwangLi Park; Georges El Fakhri; Maged Henary; Sylvain Gioux; John V Frangioni; Hak Soo Choi Journal: Chem Commun (Camb) Date: 2016-08-11 Impact factor: 6.222
Authors: Hoon Hyun; Hideyuki Wada; Kai Bao; Julien Gravier; Yogesh Yadav; Matt Laramie; Maged Henary; John V Frangioni; Hak Soo Choi Journal: Angew Chem Int Ed Engl Date: 2014-08-19 Impact factor: 15.336
Authors: Hoon Hyun; Eric A Owens; Hideyuki Wada; Andrew Levitz; GwangLi Park; Min Ho Park; John V Frangioni; Maged Henary; Hak Soo Choi Journal: Angew Chem Int Ed Engl Date: 2015-06-10 Impact factor: 15.336
Authors: Christina R Vargas; John T Nguyen; Yoshitomo Ashitate; Jason Silvestre; Vivek Venugopal; Florin Neacsu; Frank Kettenring; John V Frangioni; Sylvain Gioux; Bernard T Lee Journal: Microsurgery Date: 2015-01-09 Impact factor: 2.425
Authors: Hoon Hyun; Min Ho Park; Eric A Owens; Hideyuki Wada; Maged Henary; Henricus J M Handgraaf; Alexander L Vahrmeijer; John V Frangioni; Hak Soo Choi Journal: Nat Med Date: 2015-01-05 Impact factor: 53.440